Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

Navo, Marisa A.; Kunthur, Anuradha; Badell, Martina; Coffer, Larry; Markman, Maurie; Brown, Jubilee; Smith, Judith A.

doi:10.1016/j.ygyno.2006.04.002

Cited by 81 publications

(70 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter result is above the upper limit of the range reported in the literature (2–4%) [2,14], but we reported all HR, even if G1–2 and a low level of compliance with premedication regimens. In accordance with the international literature [24], the incidence of HR was higher in ovarian cancer.…”

Section: Discussionsupporting

confidence: 90%

A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

Piovano

Pivetta

Modaffari

et al. 2012

Gynecol Obstet Invest

View full text Add to dashboard Cite

Aims: To investigate the frequency of and predictive factors for hypersensitivity reactions (HR) to taxanes and platinum salts in a cohort of patients treated for pelvic gynecologic malignancies. Methods: The medical records of all patients with gynecologic pelvic neoplasms treated with chemotherapy at the Department of Gynecologic Oncology, AO Mauriziano Umberto I of Turin, from September 2007 through August 2008, were retrospectively reviewed. Two multivariate models, regarding carboplatin and taxane chemotherapy, respectively, were performed to evaluate the potential predictive value of various clinical features. Results: The incidence of HR was 14% (22/157). Multivariate models showed that menopausal women had a significantly lower probability of HR (OR 0.12, CI 0.02–1.13, p = 0.06 for the carboplatin model and OR 0.05, CI 0.01–0.63, p = 0.02 for the taxane model) while a history of systemic hypersensitivity was associated with a higher but non-significant risk of HR (OR 2.64, CI 0.78–8.95, p = 0.11, for the carboplatin model and OR 3.42, CI 0.94–12.45, p = 0.06, for the taxane model). Conclusion: We confirmed a history of hypersensitivity as a risk factor for HR. Other larger cohorts should be analyzed: we need to find new predictive factors in order to select women who should be submitted to experimental prophylactic strategies.

show abstract

Section: Discussionsupporting

confidence: 90%

A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

Piovano

Pivetta

Modaffari

et al. 2012

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…259,263 A recent study suggests that that premedication with H 1 and H 2 antagonists may prevent hypersensitivity reactions. 264 Another recent study describes a successful 6-hour desensitization protocol that allows for ongoing drug treatment in previously sensitized patients. 265 Interestingly, cisplatin has also been safely administered to 13 carboplatin-sensitive patients without reaction.…”

Section: Platinum Agentsmentioning

confidence: 99%

Chemotherapeutic agents and the skin: An update

Heidary

Naik

Burgin

2008

Journal of the American Academy of Dermatology

219

138

View full text Add to dashboard Cite

“…The reported incidence of HR in patients who received more than 7 courses of carboplatin is 26.7%, 1) which is similar to that reported previously by our group (23.2%) in patients with gynecologic cancer. 4) Although the risk of carboplatinrelated HR is thought to be associated with previous history of drug allergy, prolonged platinum-free interval or high dose of carboplatin, [2][3][4][5] these parameters are not very sensitive for the prediction of HR. Intradermal injection of carboplatin has also been used for the diagnosis of carboplatin-related HR, and the reported sensitivity and false-positivity of the test are 85.7% and 1.5%, respectively, in patients with gynecologic cancer.…”

mentioning

confidence: 99%

Evaluation of Basophil CD203c as a Predictor of Carboplatin-Related Hypersensitivity Reaction in Patients with Gynecologic Cancer

Iwamoto

Abe

Tabata

et al. 2012

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

The incidence of hypersensitivity reaction (HR) to carboplatin has been reported to increase after repeated use of the drug. However, a reliable ex vivo test to predict HR to carboplatin is not currently available. We evaluated the clinical usefulness of measuring basophil CD203c to predict carboplatin-related HR in this prospective case-control study conducted at Mie University Hospital between October 2009 and September 2010. Eleven patients had history of carboplatin-related HR within the past 3 years, and 19 had no history of HR after receiving more than 5 courses of carboplatin therapy. Six of these 19 patients developed carboplatin-related HR during the study period. The CD203c basophils (%) and the mean fluorescence intensity (MFI) were analyzed on a flow cytometer and compared between patients with and without HR. Changes in the CD203c expression on basophils before and after HR were also assessed in patients who developed HR during the study period. The median CD203c basophils (%) and ΔMFI after 30-min exposure to 50 µg/mL carboplatin were significantly higher in patients with HR (3.5% and ΔMFI 9.0) compared with those without (2.2% and ΔMFI 0.4) (p<0.05). In particular, these values were significantly higher in patients with grade 4 anaphylaxis (10.6% and ΔMFI 22.0). All five patients who developed grade 2-4 anaphylaxis during the study period had high CD203c basophils (%) and/or increased ΔMFI on the day before HR. The results suggest that basophil CD203c may be a promising biomarker for the prediction of severe carboplatinrelated anaphylaxis.

show abstract

Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

Cited by 81 publications

References 22 publications

A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

A Search for Predictive Factors for Hypersensitivity Reactions to Paclitaxel and Platinum Salts in Chemotherapy for Gynecologic Pelvic Neoplasms

Chemotherapeutic agents and the skin: An update

Evaluation of Basophil CD203c as a Predictor of Carboplatin-Related Hypersensitivity Reaction in Patients with Gynecologic Cancer

Contact Info

Product

Resources

About